论文部分内容阅读
Celgene公司和美国国立癌症研究所(NCI)开展小规模的实验,研究沙利度胺(反应停)与紫杉醇和卡铂合用治疗非小细胞性肺癌。这一研究是由NCI在Wisconsin大学的癌症治疗评估计划所启动的按10例病人为一小组研究其毒性耐受性、不良反应、病情稳定性及
Celgene and the United States National Cancer Institute (NCI) conducted a small-scale experiment to study the combination of thalidomide (response) with paclitaxel and carboplatin for the treatment of non-small cell lung cancer. This study was initiated by NCI at the Cancer Treatment Assessment Program at the University of Wisconsin. A panel of 10 patients was studied for toxicity, adverse events, and disease stability.